profit from every $100 of sales.
$0$100
SELLAS Life Sciences Group
$7.86-2.12% today
+438.4% in 1 year
1-year low $1.391-year high $15.46
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What SELLAS Life Sciences Group sold, what it kept, and what it did with the cash.
Sales went from $1.00 million in 2022 to $0 in 2025, with -$26.9 million of profit last year.
SalesProfit
SELLAS Life Sciences Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SELLAS Life Sciences Group | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads SELLAS Life Sciences Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| 1 | 0 | – | – | |
| -32 | -38 | -32 | -28 | |
| -32 | -38 | -32 | -28 | |
| -41 | -37 | -31 | -27 | |
| -2.13 | -1.34 | -0.50 | -0.25 | |
| 90.0% | – | – | – | |
| -3,195.0% | – | – | – | |
| -4,130.1% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 21 | 6 | 19 | 78 |
| Cash | 17 | 3 | 14 | 72 |
| Total debt | 1 | 1 | 1 | 1 |
| Total liabilities | 16 | 14 | 10 | 7 |
| 5 | -8 | 9 | 71 | |
| 19 | 28 | 61 | 109 | |
| -435.5% | – | -237.9% | -31.1% | |
| -851.4% | 468.2% | -326.3% | -37.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -24 | -31 | -35 | -28 | |
| 5 | 6 | – | – | |
| -28 | -37 | -35 | -28 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 2 | 2 | 2 |
Valuation
- –
- –
- –
- 12.2×
- 1,602.3×
- –
- –
- -1.8%
- -2.6%
- 0.0%
Profitability
- 90.0%
- -3,195.0%
- -4,130.1%
- 0.0%
- -29.1%
- -122.9%
- -47.1%
- -25.8%
- -29.2%
- –
Growth
- –
- –
- +19.8%
- –
- +62.9%
Financial health
- -0.5×
- 0.01
- 0.8%
- –
- 17.22
- 17.22
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 963
Bottom 28%of 991
What analysts expect
- Average price target
- $2.80
- Range
- $2.40 – $3.20
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.05 | -0.06 | +16.7% |
| Mar 19, 2026 | -0.05 | -0.06 | +21.0% |
| Nov 12, 2025 | -0.06 | -0.06 | +5.3% |
| Aug 12, 2025 | -0.07 | -0.08 | +16.0% |
| May 13, 2025 | -0.07 | -0.10 | +30.0% |
| Mar 20, 2025 | -0.08 | -0.11 | +27.3% |
| Nov 13, 2024 | -0.10 | -0.13 | +23.1% |
| Aug 13, 2024 | -0.13 | -0.16 | +18.8% |
News
Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In FocusYahoo Finance · Oct 30, 2026Why Are Nasdaq Futures Soaring Premarket? NBIS, MU, TSLA, SPCX, ASTS, SLS Stocks In FocusYahoo Finance · Oct 19, 2026Why Are Nasdaq, S&P 500 Futures Subdued Premarket? NVDA, AAPL, INTC, CRWD, RKLB, SLS Stocks In FocusYahoo Finance · Aug 31, 2026Why Are Nasdaq, S&P 500 Futures Slipping Premarket? NVDA, INTU, CRWD, CRM, CRML, SLS Stocks In FocusYahoo Finance · Aug 26, 2026Why Are Nasdaq, S&P 500 Futures Falling Premarket? NVDA, BABA, PSKY, SLS, AAOI, SPCX, RKLB Stocks In FocusYahoo Finance · Aug 24, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
42No pass
Philip Fisher
57No pass
Peter Lynch
10No pass
Joel Greenblatt
2No pass
Charlie Munger
58No pass
Terry Smith
57No pass
Questions about SELLAS Life Sciences Group
Is SELLAS Life Sciences Group a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SELLAS Life Sciences Group AI analysis
What does SELLAS Life Sciences Group do?
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. It is in Biotechnology.
Does SELLAS Life Sciences Group pay a dividend?
No. SELLAS Life Sciences Group does not pay a dividend at the moment.
Is SELLAS Life Sciences Group stock halal?
Yes. SELLAS Life Sciences Group passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has SELLAS Life Sciences Group stock done over the past year?
Up 438.4% over the past twelve months, to $7.86. It traded between $1.39 and $15.46 and is 49.2% below its high.
Who are SELLAS Life Sciences Group's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with SELLAS Life Sciences Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.